Allergan Aesthetics’ Boey: The Pioneering Fast-Acting Neurotoxin Earns Approval in Europe
A monumental advancement in aesthetic medicine has been achieved. Allergan Aesthetics, an AbbVie company and the creator of Botox Cosmetic, has been granted European Commission approval for Boey (trenibotulinumtoxinE). This is the world’s first rapid-onset, short-duration botulinum neurotoxin serotype E for cosmetic use.
What distinguishes Boey from all other neurotoxins in the market is its exceptional speed. Clinical trials have shown that results can manifest in as little as eight hours post-treatment. This is a stark contrast to the days or even weeks typically necessary with traditional Botox. Uniquely, the effects naturally dissipate in just two to three weeks, as opposed to the three-to-four months associated with conventional botulinum toxin type A treatments.
The treatment is specifically sanctioned for the temporary enhancement of glabellar lines — the vertical frown lines between the eyebrows — in adults. The European Commission authorization is applicable across all 30 European Economic Area countries. This builds upon Health Canada’s earlier approval of Boey in June 2026. The approval was backed by two Phase 3 randomized, double-blind, placebo-controlled clinical trials involving 725 adults with moderate to severe glabellar lines.
Experts and manufacturers tout Boey as an ideal “try-before-you-commit” option for the increasing number of individuals intrigued by facial injectables but reluctant to commit to longer-lasting results. A company survey discovered that 80% of respondents were receptive to learning about new treatments and 79% desired a preview of the outcome before fully committing.
Source: NewBeauty — The World’s First Fast-Acting Neurotoxin Just Got Approved in Europe